Recombinant Human TRAP/CD40L Protein

Name: Recombinant Human TRAP/CD40L Protein
Brand: Beta LifeScience
SKU: BLA-11160P
Availability: InStock

Collections: Antibody / cell therapy targets, Antibody therapeutic / adc target proteins, Car-nk targets proteins, Cluster of differentiation (cd) proteins, Co-stimulatory receptors, Cytokines and growth factors, Featured cd protein molecules, Recombinant proteins, Tumor necrosis factors and receptors (tnfs)

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Host Species	Human
Accession	P29965
Synonym	CD 40L CD154 CD40 antigen ligand CD40 ligand CD40 ligand, soluble form CD40-L CD40L CD40L_HUMAN CD40LG gp39 hCD40L HIGM1 IGM IMD3 T B cell activating molecule T BAM T-cell antigen Gp39 TNF-related activation protein TNFSF5 TrAP Tumor necrosis factor (ligand) superfamily member 5 Tumor necrosis factor ligand superfamily member 5
Description	Recombinant Human TRAP/CD40L Protein was expressed in E.coli. It is a Full length protein
Source	E.coli
AA Sequence	MQKGDQNPQI AAHVISEASS KTTSVLQWAE KGYYTMSNNL VTLENGKQLT VKRQGLYYIY AQVTFCSNRE ASSQAPFIAS LWLKSPGRFE RILLRAANTH SSAKPCGQQS IHLGGVFELQ PGASVFVNVT DPSQVSHGTG FTSFGLLKL
Molecular Weight	29 kDa
Purity	>95% by SDS-PAGE .
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity	Activity of HEK-BlueTMCD40L cells ED50 -‰¤50 ng/mL ; -‰¥ 2.0 x 10^4 units/mg.
Formulation	Lyophilised
Stability	The recombinant protein samples are stable for up to 12 months at -80°C
Reconstitution	See related COA
Unit Definition	For Research Use Only
Storage Buffer	Shipped at Room Temperature. Upon delivery aliquot. Store at -20°C or -80°C. Working aliquots stored with a carrier protein are stable for at least 3 months at -20°C to -80°C..

Target Details

Target Function	Cytokine that acts as a ligand to CD40/TNFRSF5. Costimulates T-cell proliferation and cytokine production. Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation. Induces the activation of NF-kappa-B. Induces the activation of kinases MAPK8 and PAK2 in T-cells. Induces tyrosine phosphorylation of isoform 3 of CD28. Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4. Involved in immunoglobulin class switching.; Acts as a ligand for integrins, specifically ITGA5:ITGB1 and ITGAV:ITGB3; both integrins and the CD40 receptor are required for activation of CD40-CD40LG signaling, which have cell-type dependent effects, such as B-cell activation, NF-kappa-B signaling and anti-apoptotic signaling.
Subcellular Location	Cell membrane; Single-pass type II membrane protein. Cell surface.; [CD40 ligand, soluble form]: Secreted.
Protein Families	Tumor necrosis factor family
Database References	HGNC: 11935 OMIM: 300386 KEGG: hsa:959 STRING: 9606.ENSP00000359663 UniGene: Hs.592244
Associated Diseases	Immunodeficiency with hyper-IgM, type 1 (HIGM1)
Tissue Specificity	Specifically expressed on activated CD4+ T-lymphocytes.

Gene Functions References

this study reports the clinical and CD40L genetic features of six Iranian hyper IgM syndrome patients PMID: 30081731
Overexpression of CD40L-WT/CD40L-M in CD40+ NSCLC cells increased SA-beta-gal staining activity and inhibited DNA synthesis and cell proliferation. PMID: 30078020
T cell-stimulated CLL cells actively recruited monocytes, and CD40L was identified as the responsible T-cell factor that mediated recruitment. PMID: 28971904
this study shows that decreased serum levels of soluble CD40L correlate in treated patients with Relapsing-Remitting Multiple Sclerosis PMID: 29050818
In conclusion, we described a new pathway of platelet-monocyte interaction, mediated by sCD40L and oxidative stress that may contribute to the progression of endothelial dysfunction during Shiga toxin 2-associated hemolytic uremic syndrome. PMID: 29068360
show that sCD40L/alpha5beta1 interaction leads to platelet activation as evaluated in the human whole blood PMID: 26719354
In this first X chromosome-wide association study of adult patients with IBD, we identified an IBD susceptibility locus with genome-wide significance at rs2427870 on chrXq26.3, located 66 kbp upstream of CD40LG and 83.4 kbp upstream of ARHGEF6 [OR, 1.22; combined p = 3.79 x 10-15]. PMID: 28333213
Study indicates that the rs1126535C/T polymorphism of CD154 gene was involved in the progression of Chinese SLE patients, probably by affecting the expression of CD154. PMID: 28550400
study found that plasma CD40L was associated with acute chest syndrome (ACS), and that sickle cell anemia (SCA)patients with a lifetime history of ACS (ACS+) presented significantly higher plasma CD40L and TSP-1 than patients who had never experienced ACS (ACS-) PMID: 28609750
this paper demonstrates importance of CD40/CD40L signaling on IL-10-producing regulatory B cells in Chinese children with Henoch-Schonlein purpura nephritis PMID: 27837410
Soluble CD40 ligand derived from serum is not correlated with early stage of multiple sclerosis. PMID: 28619427
Analysis of the early events after receptor engagement revealed that both TNF and CD40L activate the classical NF-kappaB pathway, and confirm activation of the alternative by the latter. Furthermore, using genetic and pharmacological inhibition of the classical pathway we show that activation of the alternative occurs independently of the former. This reveals insights into NF-kappaB signaling by CD40L and TNF in endoth... PMID: 29183724
CD40L, more than IL-6, or TNF-alpha, constitutes a predictor to explain polycystic ovary syndrome and associated features PMID: 27572328
Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in focal segmental glomerulosclerosis. PMID: 29155846
Plasma sCD40L levels were elevated in systemic lupus erythematosis patients who had positive anti-phospholipid antibodies and experienced arterial thrombosis, suggesting that enhanced release of sCD40L through platelet activation presumably by aPL could contribute to the development of atherothrombotic disease. PMID: 28421990
Higher concentrations of CD40L in patients with limited cutaneous form in our study might suggest a role for CD40/CD40L pathway in vascular pathology of systemic sclerosis. PMID: 27392528
we also report for the first time that the rs1126535 C allele (CD40L gene) may predict a worse response after gastric bypass in morbidly obese patients PMID: 27681093
Serum levels of sCD40L and MMP-9 are associated with the stability of carotid plaques. PMID: 28642174
studies identify a novel molecular mechanism of regulation of CD40L by the transcription factor GLI2 in the tumor microenvironment downstream of CCR3 signaling PMID: 28461568
data suggest that therapeutic CD40-CD40L blocking agents may prove efficacious not only in early and established rheumatoid arthritis (RA), but also in inhibiting the progression of the disease from arthralgia or undifferentiated arthritis to RA PMID: 28455435
CD4(+) T cells that coexpress CD57 and CD154, which are exclusively present in cytomegalovirus-positive individuals. PMID: 27566833
Serum CD40L levels were elevated in both neuromyelitis optica and multiple sclerosis patients. PMID: 27725124
plasma PGE2 is correlated with the prevention of IVIG resistance and CAL formation through CD40L in KD PMID: 27525421
This study provides the first evidence that human circulating group 2 innate lymphoid cells can express CD154 and stimulate the production of IgE by B lymphocytes through IL-25/IL-33 stimulation or TLR triggering PMID: 27576126
data also demonstrated that the CD154-triggered inhibition of the Fas-mediated cell death response was dependent on a suppression of caspase-8 cleavage, but independent of de novo protein synthesis or alterations in Fas expression on cell surface. PMID: 27391025
These results suggest soluble CD40L could have a prognostic value in ST-elevation myocardial infarction patients. PMID: 27172386
persistence of helper T-cell-derived CD40L on or in B cells could permit sustained CD40 signaling enabling survival and proliferation of antigen-presenting B cells following brief interactions with helper T cells in vivo in germinal centers. PMID: 27753080
These results demonstrate the feasibility of engineered nuclease-directed gene repair to restore endogenously regulated CD40L, and the potential for its use in T-cell therapy for X-HIGM syndrome. PMID: 26903548
Hypertensives showed significantly enhanced soluble CD40L levels compared to normotensive controls PMID: 27090943
The levels of sCD40l have no influence on survival or cardiovascular events and mortality in haemodialysis patients in a long-term follow-up PMID: 27295448
CD40L gene polymorphism was found to be associated with severe falciparum malaria in Indian population especially in severe malarial anaemia. PMID: 28352049
While CD40 expression tends to be relatively high in the peritumoral dermis of epithelial carcinomas, the expression of CD40L in mast cells is low in the same peritumoral area, compared with the opposite findings in psoriasis and actinic keratosis. PMID: 28267402
Increased serum sCD40L levels may be related to angiogenesis in patients with multiple myeloma (MM). This protein has potential clinical usefulness in MM and may be considered as an additional prognostic marker. The correlation of sCD40L with beta-thromboglobulin may indicate that in patients with MM sCD40L derives from activated platelets. PMID: 27243341
Primary Aldosteronism is related to platelet activation, expressed as higher plasma values of soluble CD40L and soluble P-selectin values. PMID: 27101095
Given the crucial role of sCD40L, this haplotype study in a transfusion model may be helpful to further determine the role of haplotypes in inflammatory clinical settings. PMID: 27094978
Overexpression of CD154 on CD4(+)T cells is unlikely to be central to the pathogenesis of idopathic thrombocytopenic purpura, and other immune dysfunctions should be targeted for therapy purposes. PMID: 26183367
the serum levels of the soluble factors sCD40L and CXCL1 are not associated with endometriosis and are not suitable as biomarkers for disease diagnosis. PMID: 27190986
Increased sCD40L plasma levels are associated with the presence of insulin resistance and not the state of glucose tolerance. PMID: 26934129
we report that Kv1.3-NPs reduced NFAT activation and CD40L expression exclusively in CD45RO(+) T cells. Furthermore, Kv1.3-NPs suppressed cytokine release and induced a phenotype switch of T cells from predominantly memory to naive. PMID: 26994905
mCD40L-induced cell death mediated by NORE1A expression appeared to be independent of mCD40L-induced cell death mediated by sustained JNK activation since NORE1A inhibition did not affect JNK phosphorylation and vice versa PMID: 26986513
diagnostic value of soluble CD40 ligand (sCD40L) and vascular endothelial growth factor (VEGF) for Alzheimer's disease PMID: 26706786
Study allows identify significant different genetic heterogeneity between two investigated populations (France and Tunisia) and revealed discrepancies in the prevalence of CD40LG polymorphisms that may be explained by ethnic and geographic differences. PMID: 26577033
concentrations of the C-reactive protein, myeloperoxidase and soluble CD40 ligand taken from peripheral vein were closely similar to the concentration found in coronary blood of ACS patients PMID: 26576922
Studies suggest that the CD40/CD154 pathway represents a promising potential therapeutic target for the prevention of transplantation rejection. PMID: 26268734
Three single-nucleotide polymorphisms (SNPs) of the TLR8, CD40LG and IRAK1 genes on the X chromosome were genotyped. PMID: 26043172
plasma soluble CD40L levels are reduced by antiplatelet therapy with clopidogrel, but not associated with long-term ischemic outcomes in unselected consecutive aspirin-treated patients undergoing cardiac catheterization. PMID: 26237513
The study findings showed that plasma sCD40L, fetuin-A, and PAPP-A levels are associated with carotid plaque formation and instability. PMID: 26214492
CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells. PMID: 26313915
CD40 ligand induces von Willebrand factor release from endothelial cells PMID: 25608503
Higher plasma soluble CD40L levels on presentation are associated with clinical severity and have potential to be a good prognostic biomarker of aneurysmal subarachnoid hemorrhage. PMID: 25944664

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.